Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA

被引：0
|
作者：
Lang Zheng
Wenjing Wang
Qiu Sun
机构：
[1] West China Hospital,Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy
[2] Sichuan University,West China Medical Publishers, West China Hospital
[3] Sichuan University,undefined
来源：
Signal Transduction and Targeted Therapy | / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] 2023 in review: FDA approvals of new medicines
    Kinch, Michael S.
    Kraft, Zachary
    Schwartz, Tyler
    [J]. DRUG DISCOVERY TODAY, 2024, 29 (05)
  • [42] FDA Guidance and New Drug Approvals
    Walker, Scot
    [J]. HOSPITAL PHARMACY, 2018, 53 (06) : 360 - 362
  • [43] Pharmaceuticals - Drug approvals from the FDA
    不详
    [J]. EUROPEAN CHEMICAL NEWS, 1997, 68 (1783): : 31 - 31
  • [44] Erratum: 2010 FDA drug approvals
    Asher Mullard
    [J]. Nature Reviews Drug Discovery, 2011, 10 (3) : 237 - 237
  • [45] An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023)
    Elbaz, Josh
    Haslam, Alyson
    Prasad, Vinay
    [J]. CANCER MEDICINE, 2024, 13 (08):
  • [46] Erratum: 2017 FDA drug approvals
    Asher Mullard
    [J]. Nature Reviews Drug Discovery, 2018, 17 (2) : 150 - 150
  • [47] 2023 FDA approvals: unprecedented volume at moderate value
    Baedeker, Mathias
    Ringel, Michael S.
    Moeller, Clemens C.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (02) : 98 - 98
  • [48] 2023 FDA approvals: unprecedented volume at moderate value
    Mathias Baedeker
    Michael S. Ringel
    Clemens C. Möller
    [J]. Nature Reviews Drug Discovery, 2024, 23 : 98 - 98
  • [49] FDA moves to speed cancer drug approvals
    Reynolds, T
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (08) : 491 - 491
  • [50] Analysis of FDA approvals of targeted anticancer combination regimens
    Brown, Victoria Tkacz
    Cho, Victoria
    Parkey, Shannon
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (23) : 1938 - 1942
12345